WT1-235肽体外抗肿瘤效应的研究  

Anti-tumor effects of WT1-235 peptide

作　　者：樊卫平[1] 谢艳云[1] 宋玉靖[1] 王宏伟 郝彦琴[1] 苑晓娟[1] 

机构地区：[1]山西医科大学微生物免疫教研室,太原030001 [2]第二临床学院血液病研究所

出　　处：《免疫学杂志》2011年第5期377-380,共4页Immunological Journal

基　　金：国家自然基金专项(81041081);山西省科技攻关项目(20090311057-7);山西医科大学博士启动基金(200601)

摘　　要：目的探索WT1肽体外抗肿瘤效应。方法合成含HLA-A*0201锚定位点的9个氨基酸的WT1-235肽。PCR-SSP法筛选HLA-A*0201健康供者并鉴定细胞株HLA-A基因型别,RT-PCR鉴定靶细胞株WT1表达与否。体外分离HLA-A*0201型别的外周血单个核细胞(PBMCs),培养树突状细胞(DC),负载WT1肽并刺激活化同源淋巴细胞,进行体外CTLs杀伤靶细胞的细胞毒试验。结果荷肽DC活化的CTLs对高表达WT1的HLA-A*0201型别细胞株SW48的杀伤效应高于不表达WT1的HLA-A*0201型别的人T细胞,也高于表达WT1但非HLA-A*0201型别的K562细胞(P<0.05)。结论 WT235-242肽具有体外抗肿瘤效应并受MHC限制。We aimed to investigate the anti-tumor effects of WT1 peptide in vitro.Firstly,A 9-mer WT1 peptide（WT1-235） containing HLA-A＊0201 binding motifs was synthesized.Then we identified the HLA-A＊0201 gene type of healthy donor and the target cells by PCR-SSP.The expressions of WT1 gene in target cells were identified by RT-PCR;the peripheral blood mononuclear cells（PBMCs） of HLA-A＊0201 healthy donor were isolated and the dendritic cells（DCs） were cultured from those PBMCs in vitro.The homologous specific CTLs were activated by WT1 peptide-loaded DCs,and the cytotoxicity test of the CTLs to target cells was tested in vitro.We found that the cytotoxic activity of the CTLs to SW480 cells which were WT1-expressing and HLA-A＊0201-positive were more effectively than those to HLA-A＊0201-positive human T cells without WT1 expression and to K562 cells without HLA-A＊0201 site and WT1 expression（P〈0.05）.This result suggested that the WT235-242 peptide do have anti-tumor effect in vitro and the specific cytotoxicity is restricted exactly in the same major histocompatibility complex（MHC） site.

关 键 词：WT1 肽疫苗 树突状细胞 CTL 抗肿瘤 

分 类 号：R730.2[医药卫生—肿瘤]